{
    "clinical_study": {
        "@rank": "98963", 
        "acronym": "DREAM", 
        "arm_group": {
            "arm_group_label": "fluconazole", 
            "description": "Infant Subjects who are treated with fluconazole"
        }, 
        "brief_summary": {
            "textblock": "To collect the efficacy and safety information of fluconazole on infant subjects related to\n      their appropriate use in daily practice."
        }, 
        "brief_title": "Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Deep Mycosis", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or Female under age of seven patients who are prescribed fluconazole (Diflucan)\n             for antifungal treatment or prophylaxis administration.\n\n        Exclusion Criteria:\n\n          -  Subject of seven years or more who have been prescribed fluconazole."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The patients whom an investigator involving A0561022 prescribes the fluconazole\n        (Diflucan)."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680458", 
            "org_study_id": "A0561022"
        }, 
        "intervention": {
            "arm_group_label": "fluconazole", 
            "description": "Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.\nCryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.\nProphylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.\nAbsolute doses exceeding 600 mg/day are not recommended.", 
            "intervention_name": "Fluconazole", 
            "intervention_type": "Drug", 
            "other_name": "Diflucan"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antifungal Agents", 
                "Fluconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "antifungal treatment", 
            "prophylaxis", 
            "administration", 
            "Japanese", 
            "infants", 
            "fluconazole", 
            "Diflucan", 
            "Regulatory Post Marketing Commitment Plan."
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0561022&StudyName=Diflucan%20Research%20For%20Infant%20Evaluation%20Of%20Antifungal%20Treatment%20And%20Prophylaxis%20Medication"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Investigation Of Diflucan For Infant Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit", 
            "safety_issue": "Yes", 
            "time_frame": "13 weeks"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}